NBY
NovaBay Pharmaceuticals, Inc.
Biotechnology
Market Cap$11M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NBY vs CTXR
Revenue, margins, valuation, and 5-year total return — side by side.
CTXR
Citius Pharmaceuticals, Inc.
Biotechnology
Market Cap$12M
5Y Perf.-95.9%
NBY vs CTXR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NBY | CTXR |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $11M | $12M |
| Revenue (TTM) | $3M | $0.00 |
| Net Income (TTM) | $3M | $-37M |
| Gross Margin | 54.6% | — |
| Operating Margin | -273.0% | — |
| Total Debt | $2M | $2M |
| Cash & Equiv. | $430K | $4M |
NBY vs CTXR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NBY
CTXR
| Stock | May 20 | Apr 26 | Return |
|---|---|---|---|
| NovaBay Pharmaceuti… (NBY) | 100 | 0.0 | -100.0% |
| Citius Pharmaceutic… (CTXR) | 100 | 4.1 | -95.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NBY vs CTXR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NBY leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
NBY
NovaBay Pharmaceuticals, Inc.
The Income Pick
NBY carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 2.43
- Rev growth -6.4%, EPS growth 98.2%, 3Y rev CAGR -1.4%
- Lower volatility, beta 2.43, current ratio 0.68x
Best for: income & stability and growth exposure
CTXR
Citius Pharmaceuticals, Inc.
The Long-Run Compounder
CTXR is the clearest fit if your priority is long-term compounding.
- -99.9% 10Y total return vs NBY's -100.0%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NBY | -6.4% revenue growth vs CTXR's -100.0% |
| Quality / Margins | NBY | 114.6% margin vs CTXR's -0.1% |
| Stability / Safety | NBY | Beta 2.43 vs CTXR's 2.76 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NBY | +102.8% vs CTXR's -6.2% |
| Efficiency (ROA) | NBY | 93.0% ROA vs CTXR's -28.6%, ROIC -217.0% vs -39.5% |
NBY vs CTXR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
NBY vs CTXR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNBYLAGGINGCTXR
CTXRCitius Pharmaceutical…
0leads
NBYNovaBay Pharmaceutica…
1leads
6 Total Categories
CATEGORYLEADERvs CTXRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
NBY1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — NBY and CTXR each lead in 1 of 2 comparable metrics.
Income & Cash Flow (Last 12 Months)
NBY and CTXR operate at a comparable scale, with $3M and $0 in trailing revenue. On growth, NBY holds the edge at -78.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | NBYNovaBay Pharmaceu… | CTXRCitius Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $3M | $0 |
| EBITDAEarnings before interest/tax | -$8M | -$38M |
| Net IncomeAfter-tax profit | $3M | -$37M |
| Free Cash FlowCash after capex | -$7M | -$27M |
| Gross MarginGross profit ÷ Revenue | +54.6% | — |
| Operating MarginEBIT ÷ Revenue | -2.7% | — |
| Net MarginNet income ÷ Revenue | +114.6% | — |
| FCF MarginFCF ÷ Revenue | -2.5% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -78.7% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +63.3% | +74.1% |
Evenly matched — NBY and CTXR each lead in 1 of 2 comparable metrics.
Valuation Metrics
NBY leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | NBYNovaBay Pharmaceu… | CTXRCitius Pharmaceut… |
|---|---|---|
| Market CapShares × price | $11M | $12M |
| Enterprise ValueMkt cap + debt − cash | $13M | $9M |
| Trailing P/EPrice ÷ TTM EPS | -0.74x | -0.19x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.16x | — |
| Price / BookPrice ÷ Book value/share | — | 0.09x |
| Price / FCFMarket cap ÷ FCF | — | — |
NBY leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
Evenly matched — NBY and CTXR each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
NBY delivers a 198.5% return on equity — every $100 of shareholder capital generates $198 in annual profit, vs $-48 for CTXR. On the Piotroski fundamental quality scale (0–9), CTXR scores 4/9 vs NBY's 3/9, reflecting mixed financial health.
| Metric | NBYNovaBay Pharmaceu… | CTXRCitius Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | +198.5% | -48.3% |
| ROA (TTM)Return on assets | +93.0% | -28.6% |
| ROICReturn on invested capital | -2.2% | -39.5% |
| ROCEReturn on capital employed | -2.2% | -46.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | $1M | -$3M |
| Cash & Equiv.Liquid assets | $430,000 | $4M |
| Total DebtShort + long-term debt | $2M | $2M |
| Interest CoverageEBIT ÷ Interest expense | -89.97x | -143.54x |
Evenly matched — NBY and CTXR each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — NBY and CTXR each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CTXR five years ago would be worth $121 today (with dividends reinvested), compared to $13 for NBY. Over the past 12 months, NBY leads with a +102.8% total return vs CTXR's -6.2%. The 3-year compound annual growth rate (CAGR) favors NBY at -67.4% vs CTXR's -72.7% — a key indicator of consistent wealth creation.
| Metric | NBYNovaBay Pharmaceu… | CTXRCitius Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -93.6% | -22.9% |
| 1-Year ReturnPast 12 months | +102.8% | -6.2% |
| 3-Year ReturnCumulative with dividends | -96.5% | -98.0% |
| 5-Year ReturnCumulative with dividends | -99.9% | -98.8% |
| 10-Year ReturnCumulative with dividends | -100.0% | -99.9% |
| CAGR (3Y)Annualised 3-year return | -67.4% | -72.7% |
Evenly matched — NBY and CTXR each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NBY and CTXR each lead in 1 of 2 comparable metrics.
Risk & Volatility
NBY is the less volatile stock with a 2.43 beta — it tends to amplify market swings less than CTXR's 2.76 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CTXR currently trades 26.4% from its 52-week high vs NBY's 1.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NBYNovaBay Pharmaceu… | CTXRCitius Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.43x | 2.76x |
| 52-Week HighHighest price in past year | $99.75 | $2.48 |
| 52-Week LowLowest price in past year | $1.11 | $0.57 |
| % of 52W HighCurrent price vs 52-week peak | +1.9% | +26.4% |
| RSI (14)Momentum oscillator 0–100 | 42.5 | 41.1 |
| Avg Volume (50D)Average daily shares traded | 595K | 746K |
Evenly matched — NBY and CTXR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NBYNovaBay Pharmaceu… | CTXRCitius Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NBY leads in 1 of 6 categories — strongest in Valuation Metrics. 4 categories are tied.
Best OverallNovaBay Pharmaceuticals, In… (NBY)Leads 1 of 6 categories
Loading custom metrics...
NBY vs CTXR: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — NBY or CTXR?
Over the past 5 years, Citius Pharmaceuticals, Inc.
(CTXR) delivered a total return of -98. 8%, compared to -99. 9% for NovaBay Pharmaceuticals, Inc. (NBY). Over 10 years, the gap is even starker: CTXR returned -99. 9% versus NBY's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — NBY or CTXR?
By beta (market sensitivity over 5 years), NovaBay Pharmaceuticals, Inc.
(NBY) is the lower-risk stock at 2. 43β versus Citius Pharmaceuticals, Inc. 's 2. 76β — meaning CTXR is approximately 14% more volatile than NBY relative to the S&P 500.
03Which is growing faster — NBY or CTXR?
On earnings-per-share growth, the picture is similar: NovaBay Pharmaceuticals, Inc.
grew EPS 98. 2% year-over-year, compared to 43. 4% for Citius Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — NBY or CTXR?
Citius Pharmaceuticals, Inc.
(CTXR) is the more profitable company, earning 0. 0% net margin versus -73. 8% for NovaBay Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTXR leads at 0. 0% versus -59. 7% for NBY. At the gross margin level — before operating expenses — NBY leads at 66. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — NBY or CTXR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is NBY or CTXR better for a retirement portfolio?
For long-horizon retirement investors, Citius Pharmaceuticals, Inc.
(CTXR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. NovaBay Pharmaceuticals, Inc. (NBY) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CTXR: -99. 9%, NBY: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between NBY and CTXR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(NBY: -78.7% · CTXR: -100.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.